Drugs / Piperacillin/tazobactam
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05565222 | Mar 2023 → Apr 2026 | infectious disease with sepsis | Assistance Publique - Hôpitaux de Paris | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Piperacillin/tazobactam | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05565222 ↗ |
| Route | Intravenous | “Piperacillin/tazobactam : 4.5 g by intravenous route every 6 hours (adjusted in case of renal failure).” NCT05565222 ↗ |